Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelimab plus chemotherapy as neoadjuvant treatment for esophageal squamous cell carcinoma
ChiCTR2500109258Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adebrelimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Pathologic complete response rate (pCR). Started Sep 2025; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500109258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109258.